NeoPrediX completes CHF 4.1M in Series A round led by LifeCare Partners.

NeoPrediX, a Basel, Switzerland-based medical software developer for early detection and treatment of perinatal and neonatal diseases, announced completing a CHF 4.1M ($4.4M) capital investment round.

The money was raised from investors led by LifeCare Partners, and included participations from Bayern Kapital, the Eckenstein-Geigy Foundation and business angels whose name was not disclosed.

NeoPrediX, founded in 2020 as a spinoff from The Basel university bY CEO Thorsten Waloschek, develops software solutions that support medical staff in the early detection and treatment of perinatal and neonatal diseases and complications. The company has 10 employees in two locations in Basel and Regensburg.